BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24992171)

  • 1. Well-differentiated thyroid cancer with a minor poorly differentiated component: clonal heterogeneity through the prognostic role of CXCR4 and BRAF analysis.
    Rossi ED; Martini M; Capodimonti S; Straccia P; Revelli L; Lombardi CP; Pontecorvi A; Santeusanio G; Larocca LM; Fadda G
    Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):196-201. PubMed ID: 24992171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.
    Torregrossa L; Giannini R; Borrelli N; Sensi E; Melillo RM; Leocata P; Materazzi G; Miccoli P; Santoro M; Basolo F
    Mod Pathol; 2012 Jan; 25(1):46-55. PubMed ID: 21909080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
    Walts AE; Pao A; Sacks W; Bose S
    Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of BRAF mutation in thyroid papillary cancer.
    Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.
    Henke LE; Pfeifer JD; Ma C; Perkins SM; DeWees T; El-Mofty S; Moley JF; Nussenbaum B; Haughey BH; Baranski TJ; Schwarz JK; Grigsby PW
    Cancer Med; 2015 Jun; 4(6):791-9. PubMed ID: 25712893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL; Sun Y; Ding C; Lv YC; Qin HD
    Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.
    Nakazawa T; Kondo T; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Kubota T; Katoh R
    Cancer Med; 2015 Aug; 4(8):1272-80. PubMed ID: 25882744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].
    Lopes JP; Fonseca E
    Acta Med Port; 2011 Dec; 24 Suppl 4():855-68. PubMed ID: 22863493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.